The medical community has been studying Alzheimer’s disease for more than a century. But every treatment designed to break up protein clumps in the brain, the hallmark of Alzheimer’s, has proven disappointing. Nothing has been able to slow, stop or reverse the course of the disease.
Looking for new ways forward, Columbia’s Zuckerman Institute is bringing new voices to the table. These scientists are leveraging technological advances to reveal aspects of the disease long hidden from view. Working with colleagues at the Columbia University Irving Medical Center, they are laying the foundations for new approaches to combating this neurological epidemic. Discover how Columbia University is untangling Alzheimer’s disease.
Eric R. Kandel, MD, Nobel laureate, University Professor and Kavli Professor of Brain Science; Codirector of Columbia's Zuckerman Institute; Senior Investigator at the Howard Hughes Medical Institute
Richard Mayeux, MD, MSc, Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology (in the Gertrude H. Sergievsky Center and in the Taub Institute for Research on Alzheimer's Disease and the Aging Brain); Chair, Department of Neurology; Director, Gertrude H. Sergievsky Center; Codirector, Taub Institute for Research on Alzheimer's Disease and the Aging Brain; Director, Human Genetic Resources Core
Scott Small, MD, Boris and Rose Katz Professor of Neurology (in the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, the Gertrude H. Sergievsky Center and in Radiology), Director, Alzheimer's Disease Research Center
Franck Polleux, PhD, Professor of Neuroscience; Principal Investigator at Columbia's Zuckerman Institute
Daphna Shohamy, PhD, Professor of Psychology; Principal Investigator at Columbia's Zuckerman Institute
Anthony Fitzpatrick, PhD, Assistant Professor of Biochemistry and Molecular Biophysics; Member, Taub Institute for Research on Alzheimer's Disease and the Aging Brain; Principal Investigator at Columbia's Zuckerman Institute
With special thanks to: